iproniazid has been researched along with Parkinson Disease, Secondary in 2 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
| Hassler, R | 1 |
| Bak, IJ | 1 |
2 other studies available for iproniazid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |
[Submicroscopic catecholamine stores as sites of attack of the psychopharmaca, reserpine and monoamine oxidase inhibitors].
Topics: Animals; Catecholamines; Caudate Nucleus; Dopamine Antagonists; Epinephrine; Extrapyramidal Tracts; | 1966 |